IRIS
SANTORO, Armando
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.964
EU - Europa 5.276
AS - Asia 2.978
AF - Africa 823
SA - Sud America 85
Continente sconosciuto - Info sul continente non disponibili 42
OC - Oceania 19
Totale 35.187
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.640
SG - Singapore 1.647
FI - Finlandia 1.380
IE - Irlanda 1.114
NG - Nigeria 806
CN - Cina 759
IT - Italia 588
DE - Germania 531
FR - Francia 507
NL - Olanda 321
CA - Canada 316
SE - Svezia 274
GB - Regno Unito 216
TR - Turchia 185
IL - Israele 122
IN - India 110
BE - Belgio 90
RU - Federazione Russa 61
IR - Iran 33
BR - Brasile 31
CZ - Repubblica Ceca 28
CL - Cile 27
HK - Hong Kong 27
JP - Giappone 27
RO - Romania 26
A2 - ???statistics.table.value.countryCode.A2??? 21
EU - Europa 21
UA - Ucraina 20
AU - Australia 16
ES - Italia 15
PL - Polonia 13
GR - Grecia 12
KR - Corea 12
CH - Svizzera 11
IQ - Iraq 11
AR - Argentina 10
AT - Austria 10
BD - Bangladesh 10
NO - Norvegia 10
CO - Colombia 9
HU - Ungheria 7
PK - Pakistan 7
PT - Portogallo 7
SI - Slovenia 7
TW - Taiwan 7
EG - Egitto 5
ID - Indonesia 5
MX - Messico 5
PE - Perù 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
DK - Danimarca 4
EE - Estonia 4
LT - Lituania 4
MK - Macedonia 4
LY - Libia 3
MD - Moldavia 3
ML - Mali 3
NZ - Nuova Zelanda 3
VN - Vietnam 3
ZA - Sudafrica 3
AL - Albania 2
JO - Giordania 2
MO - Macao, regione amministrativa speciale della Cina 2
PH - Filippine 2
UZ - Uzbekistan 2
VE - Venezuela 2
CR - Costa Rica 1
HN - Honduras 1
HR - Croazia 1
LU - Lussemburgo 1
MA - Marocco 1
MG - Madagascar 1
MY - Malesia 1
PA - Panama 1
RS - Serbia 1
TN - Tunisia 1
UY - Uruguay 1
Totale 35.187
Salva come PNG Salva come JPEG
Città #
Wilmington 5.545
Chandler 4.578
San Mateo 2.027
Ann Arbor 1.547
Helsinki 1.375
Dublin 1.108
Singapore 1.049
Leawood 943
Princeton 913
Lawrence 912
Boardman 819
Benin City 804
Shanghai 598
New York 554
Woodbridge 516
Fairfield 511
Ashburn 496
Paris 481
Amsterdam 301
Toronto 276
Milan 225
Seattle 209
Kocaeli 180
London 175
San Diego 164
Norwalk 119
Phoenix 102
Brussels 80
Falls Church 74
Santa Clara 74
Pune 63
Los Angeles 60
Redwood City 60
Monmouth Junction 50
Abbiategrasso 39
Beijing 39
Falkenstein 39
Redmond 37
Moscow 32
Des Moines 28
Andover 27
Munich 25
Brno 22
Cambridge 21
Genoa 20
Frankfurt am Main 18
Ardabil 17
Clearwater 14
Houston 14
Nanjing 14
São Paulo 14
Zhengzhou 14
Tappahannock 13
Tokyo 13
Berlin 11
Sacramento 11
Winnipeg 11
Florence 10
Cluj 9
Hanover 9
Montréal 9
Chennai 8
Chicago 8
Las Vegas 8
Bengaluru 7
Central District 7
Gunzenhausen 7
Ljubljana 7
Montreal 7
Nanning 7
Raleigh 7
Saint Paul 7
Taipei 7
Washington 7
Basiano 6
Chengdu 6
Cologno Monzese 6
Hangzhou 6
Hasselt 6
Jacksonville 6
Kemerovo 6
La Canada Flintridge 6
Lisbon 6
Lormont 6
Munro 6
San Jose 6
Athens 5
Bergamo 5
Cupertino 5
Eden Prairie 5
Guangzhou 5
Henderson 5
Naples 5
Nuremberg 5
Santiago 5
Vancouver 5
Vienna 5
Atlanta 4
Brisbane 4
Buffalo 4
Totale 27.751
Salva come PNG Salva come JPEG
Nome #
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL) 145
Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis 136
BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors 98
Role of consolidation RT to bulky lesions of advanced Hodgkin lymphoma: results of FIL HD0801 trial 83
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer 79
Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. 75
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 74
Survival outcome and prognostic factors after pulmonary metastasectomy in sarcoma patients 73
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 73
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study 72
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 71
A new human cell line, PDSS-26, from poorly differentiated synovial sarcoma, with unique chromosomal anomalies 68
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 68
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 68
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 67
Biological characteristics and long-term outcomes in node-negative breast cancer 66
Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy 65
A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial 65
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma 64
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC) 64
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 64
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 64
A Phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small cell lung cancer. 64
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 63
PREDICTIVE VALUE OF EARLY PET DURING SALVAGE CHEMOTHERAPY IN RELAPSING/REFRACTORY HODGKIN'S LYMPHOMA (HL) PATIENTS 63
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 63
Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation. 62
A phase I clinical and pharmacokinetic study evaluating vinflumine in combination with epirubicin as first-line treatment in metastatic breast cancer 62
Intensified CHOP in non-Hodgkin's lymphoma: What we know and what we need to know 60
Early lesions in lymphomas of germinal centre B-cell derivation: evidence and hypotheses. 60
Postoperative Chemoradiotherapy or Surgery Alone for Gastric Cancer: The Plausibility of the Question and Pertinence of the Answer 60
Early restaging positron emission tomography with 18 F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true? 60
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up 60
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid 59
Pilot study with adriamycin and ifosfamide in small cell lung cancer. 59
A prospective study on survival in cancer patients with and without venous thromboembolism 59
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 59
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 59
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 59
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 59
Adjuvant volumetric modulated arc therapy compared to 3D conformal radiation therapy for newly diagnosed soft tissue sarcoma of the extremities: outcome and toxicity evaluation 58
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 58
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 58
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 57
Biomarkers in Hepatocellular Carcinoma-Letter 57
Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases 57
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 57
Tivantinib for hepatocellular carcinoma 57
Developing an adolescent and young adult (AYA) cancer program in an Italian adult high-volume cancer center. 57
Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib 56
COVID-19 and liver cancer clinical trials: not everything is lost 56
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 56
Clinical Effects of Driver Somatic mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With allogeneic Hematopoietic Stem-Cell Transplantation 56
Short schedule of cisplatin and vinorelbine: A dose-finding study in non-small-cell lung cancer 56
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma 56
A PHASE 1 SAFETY STUDY OF ONCOFID-P-B ADMINISTERED FOR 12 CONSECUTIVE WEEKS IN BCG UNRESPONSIVE/INTOLERANT PATIENTS WITH BLADDER CARCINOMA IN SITU (CIS): PRELIMINARY RESULTS 56
Assessment of prognostic factors in patients with metastatic epidural spinal cord compression (MESCC) from solid tumor after surgery plus radiotherapy: a single institution experience 56
Gene methylation in pleural mesothelioma : Correlations with clinico-pathological features and patient’s follow-up 55
Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non-Small-Cell Lung Cancer. 55
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 55
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 55
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 55
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 55
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 55
Initial chemotherapy for primary resectable large-cell lymphoma of the stomach 54
Fulvestrant for advanced male breast cancer patients: a case series 54
Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications 54
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 54
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 54
Cabozantinib for the treatment of hepatocellular carcinoma 54
Weekly non-pegylated liposomal Doxorubicin chemotherapy in heavily pre-treated patients with metastatic breast cancer 54
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer 54
Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: Can it be safely associated with fluorouracil-based chemotherapy? 54
Carminomycin vs adriamycin in advanced soft tissue sarcomas: an EORTC randomised phase II study. 54
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma 54
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 54
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma 54
Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. 54
Trastuzumab beyond progression: a challenge to translational oncology? 53
New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma 53
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 53
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 53
Lung resection for metastatic sarcomas: total survival from primary treatment. 53
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 53
Prognostic value of the immune-related transcriptome in biliary tract cancers 53
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group 53
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 53
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen 53
T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes 53
Characterisation of the immune-related transcriptome in resected biliary tract cancers 53
A. Micrometastasis in sentinel (SLN) and non sentinel lymph nodes of breast cancer: an update including clinico-pathologic impact and survaival 53
The use of radiation therapy for oligoprogressive/oligopersistent oncogene driven non small cell lung cancer: state of the art 53
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 53
A prospective observational study to evaluate G-CSF usage inpatients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice. 53
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer 53
EXTENDED-FIELD RADIOTHERAPY IN FAVORABLE STAGE IA-IIA HODGKINS-DISEASE (PROGNOSTIC ROLE OF STAGE) 52
Alternating drug combinations in the treatment of advanced Hodgkin's disease. 52
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 52
Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease 52
Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results. 52
Totale 6.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 313.634
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 313.634
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020102 0 0 0 0 0 0 0 0 0 0 6 96
2020/202110.267 96 102 102 64 111 3.181 1.427 657 2.058 1.345 90 1.034
2021/20225.041 372 72 123 1.102 86 83 202 733 426 556 1.051 235
2022/202312.822 2.015 413 1.233 1.408 1.155 1.077 32 1.083 2.225 1.121 908 152
2023/20246.772 616 733 1.518 243 195 721 323 371 87 140 697 1.128
2024/2025830 245 192 54 176 163 0 0 0 0 0 0 0
Totale 35.834